Endep (Generic) is an antidepressant with a pronounced sedative, anti-bacterial and anti-ulcer effect. Release form of the drug is produced in the form of a solution and tablets. Tablets are biconvex, round, yellow, and coated.
Endep (Generic) is a tricyclic antidepressant, which belongs to the group of non-selective inhibitors of monoamine neuronal uptake. It is characterized by sedative effects.
The mechanism of the antidepressant effect of the drug is due to the suppression of the reverse neuronal capture of catecholamines (dopamine, norepinephrine) and serotonin in the CNS.
Endep (Generic) exhibits the muscarinic cholinergic receptors in the peripheral and central nervous system, it is also characterized by peripheral antihistamine, associated with H1-receptors, and antiadrenergic effects. The substance has anti-neuralgia (central analgesic), anti-inflammatory and anti-ulcer action, and also helps to eliminate bed-wetting. The antidepressant effect develops within 2-4 weeks after the start of use.
Endep (Generic) has a high degree of absorption in the body. After oral administration, its maximum concentration is reached after about 4–8 hours. Equilibrium concentration is determined approximately 1–2 weeks after the start of therapy.
Liver dysfunctions can provoke a slowdown in the rate of metabolic processes and an increase in the content of amitriptyline in the blood plasma. For patients with renal dysfunction, excretion of nortriptyline and amitriptyline metabolites slows down, but metabolic processes proceed in a similar way.
Since Endep (Generic) binds well to plasma proteins, its removal from the body through dialysis is almost impossible.
Endep (Generic) is prescribed for the treatment of depressive states of involutional, reactive, endogenous, medicinal nature, as well as depressions, organic brain lesions, accompanied by sleep disorders, agitation, and anxiety.